Brought to you by 
Microcide and Althexis merge in all-stock transaction
04 Sep 2001
Executive Summary
Microcide Pharmaceuticals will issue 55.5mm common shares to acquire Althexis Co. in a $23.35mm stock swap. The transaction will be tax-free and accounted for using the purchase method. Microcide will change its name to Essential Therapeutics Inc. with Althexis functioning as a subsidiary.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Microcide and Althexis merge in all-stock transaction
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice